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Binocular Goggle Augmented
Imaging and Navigation System
provides real-time fluorescence
image guidance for tumor
resection and sentinel lymph node
mapping
Suman B. Mondal1,2,*, Shengkui Gao3,*, Nan Zhu4,*, Gail P. Sudlow1, Kexian Liang1,
Avik Som1,2, Walter J. Akers1, Ryan C. Fields5, Julie Margenthaler5, Rongguang Liang4,
Viktor Gruev3 & Samuel Achilefu1,2,6
The inability to identify microscopic tumors and assess surgical margins in real-time during oncologic
surgery leads to incomplete tumor removal, increases the chances of tumor recurrence, and
necessitates costly repeat surgery. To overcome these challenges, we have developed a wearable
goggle augmented imaging and navigation system (GAINS) that can provide accurate intraoperative
visualization of tumors and sentinel lymph nodes in real-time without disrupting normal surgical
workflow. GAINS projects both near-infrared fluorescence from tumors and the natural color images
of tissue onto a head-mounted display without latency. Aided by tumor-targeted contrast agents,
the system detected tumors in subcutaneous and metastatic mouse models with high accuracy
(sensitivity = 100%, specificity = 98% ± 5% standard deviation). Human pilot studies in breast cancer
and melanoma patients using a near-infrared dye show that the GAINS detected sentinel lymph
nodes with 100% sensitivity. Clinical use of the GAINS to guide tumor resection and sentinel lymph
node mapping promises to improve surgical outcomes, reduce rates of repeat surgery, and improve
the accuracy of cancer staging.

Surgical resection is the standard of care for many solid tumors such as breast cancer and melanoma, and
sentinel lymph node (SLN) mapping is used for cancer staging1. Incomplete tumor removal increases the
chances of cancer recurrence and necessitates repeat surgery, whereas inaccurate SLN identification may
misdiagnose the cancer stage. Despite recent advances in pre-operative imaging methods, surgeons rely
on visual inspection, palpation, and tactile evaluation to distinguish cancerous from uninvolved tissue
intraoperatively, leading to subjective decision-making and variable outcomes. For example, 14–50%2–4
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and 20–70%5–7 of patients undergoing melanoma in situ and breast conserving surgery, respectively,
require repeat surgery. Similarly, inaccurate SLN removal often requires additional surgical interventions8. Surgery is most effective when performed before the cancer becomes a metastatic disease.
Assessment of the SLN for the presence of cancer cells is a standard of care for staging breast cancer and
melanoma1. Conventionally, patients are injected peritumorally with 99 mTc sulfur-colloid and a visible
blue lymphotropic dye. A handheld gamma-counter is used to localize the region of highest radioactivity,
and the blue dye can be used to visualize the SLN. However, radioactive SLN tracking exposes patients
and health professionals to ionizing radiation, without SLN visualization capability. Although blue dyes
can be visualized, SLN tracking by this method is limited to inspection of only superficial lymph nodes
and requires a high dose of the dye, which may lead to harmful side-effects9,10.
The above challenges have spurred interest in developing methods for accurate intraoperative imaging
of tumors and SLNs. Conventional modalities such as magnetic resonance imaging, computed tomography, and positron emission tomography can provide exquisite anatomic and functional information11,12.
However, they are not amenable for use in the operating room (OR) due to their large hardware footprint, specialized operator requirement, prohibitive cost, and the use of ionizing radiation. Slow image
reconstruction, lack of microscopic imaging capability, and disruptive information display on a remote
monitor affects their wide adoption in the OR for real-time image guidance13. Intraoperative ultrasonography can be used for tumor detection based primarily on tissue morphology, leading to significant false
positive and negative rates14–17. As a contact based method with relatively poor resolution, intraoperative
ultrasonography is less useful for identifying tumor boundaries or microscopic tumors during open
surgeries. Advanced instruments that mimic global positioning systems have been developed, where
pre-operative computed tomography or magnetic resonance images can be projected onto the appropriate anatomical structures. These systems suffer from limitations of the pre-operative imaging method,
unsatisfactory registration due to tissue deformation and motion during surgery, and the inability to
directly interrogate boundaries of tumors.
Alternatively, optical imaging uses nonionizing radiation and simple imaging setup for real-time readout and detection of microscopic lesions18,19. In particular, near-infrared (NIR) fluorescence imaging in
the 700–900 nm range is attractive because the low absorption by intrinsic photoactive biomolecules
minimizes tissue autofluorescence and facilitates thick tissue assessment. The use of nonionizing radiation decreases safety hazards in the OR18–20. Additionally, several tumor-targeted optical contrast agents
have been developed21 including peptide22 and nanoparticle-based agents with promising features23.
These advantages have generated interest in NIR fluorescence image-guided surgery (NIR-FIGS). To
date, several NIR-FIGS systems have been developed, and successfully used for intraoperative tumor
imaging and SLN mapping (SLNM), including FLARE24, Fluobeam25, SPY26, and Hamamatsu PDE27.
However, each of these systems have some limitations, including the use of bulky hardware, potentially
disruptive information display on a remote monitor, mismatch between the system’s and surgeon’s field
of view (FOV), and require support from other workers to control the device.
Adaptation of head-mounted displays (HMDs) for surgery28–33 could overcome the issue of disruptive information display. We have previously demonstrated the feasibility of using wearable cameras and
HMDs for FIGS34–36. Our initial prototypes used a monocular projection eyepiece, which posed perception problems during surgery, or a binocular system, which only captured white light reflectance and
fluorescence images sequentially using the same sensor, thereby preventing display of real-time composite color-fluorescence images. Additionally, the issues of camera and user FOV mismatch, bulky design,
non-optimized optics, and fast processing to generate real-time color-fluorescence composite images
with minimum latency remain unaddressed. The primary goal of this study is to test the hypothesis
that simultaneous, sensitive detection of color and NIR fluorescence information, fast image processing
and image output via an HMD would allow non-disruptive access to accurately co-registered color-NIR
images for real-time image guidance in oncologic surgery. Toward this goal, we have developed a new
wearable goggle aided imaging and navigation system (GAINS) and evaluated the accuracy of using
the well-characterized system for real-time intraoperative tumor visualization and image-guided tumor
resection in small animals, as well as SLNM in human breast cancer and melanoma patients.

Results

Development of GAINS. The accuracy of image guidance depends on the sensitivity and resolu-

tion of the system, as well as the accuracy of fluorescence to color image overlay. The system detection
sensitivity is determined by the fluorescence detection sensitivity because the visible light channel has
abundant signal compared to the photon-starved fluorescence channel. The system performance is determined by the sensor and optics of the system, with a smaller sensor pixel pitch and smaller lens aperture
leading to higher resolution and larger depth of focus respectively, but with low fluorescence detection.
Thus there is a trade-off when using a lower-resolution sensor with larger pixel pitch and large aperture
lens with lower depth of focus that allows high fluorescence signal capture for more sensitive detection. Furthermore, the requirement of wearability imposed additional restrictions of having a compact,
lightweight, and ergonomic design. These factors precluded the use of different cameras with dedicated
lenses for both color and fluorescence channels, and large aperture heavy glass lenses that could capture
very large amount of fluorescence signal. The amount of fluorescence signal collected may be increased
by using large exposure times. However, the requirement of real-time image guidance constrained the

Scientific Reports | 5:12117 | DOI: 10.1038/srep12117

2

www.nature.com/scientificreports/

Figure 1. GAINS. (a) Schematic demonstrates the information flow through different modules of the
system. (b) Photograph of the NIR source. (c) Photograph of the integrated display and imaging module,
along with the processing module, which are worn by the user.

imaging exposure to acquire both fluorescence and color information. Therefore, the challenges in developing the GAINS were achieving sensitive simultaneous imaging in the photon-saturated color channel
and photon-starved fluorescence channel, real-time image processing, and non-disruptive display while
maintaining a wearable form factor. We overcame these challenges by developing a single lens, color-NIR
(Supplementary Fig. S3), and compact lightweight camera (Supplementary Table S1), with independent
exposure times for both sensors and a spatial resolution of 320 μ m (Supplementary Table S1). GAINS
conceptual design is summarized in Fig. 1a. The processing unit generates co-registered composite
color-fluorescence images, which are displayed in real-time via a lightweight and high-resolution HMD
unit. The NIR source (Fig. 1b) consists of 760 nm light-emitting diodes (LEDs) with 769 ±  41 nm bandpass filter. The display module consists of a 1080p high-resolution HMD. Adjustable mechanical mounting and a counter balance for the imaging module were added to match the camera’s weight and user
FOV for improved user experience (Fig. 1c). Additional information on the system development can be
found in the Materials and Methods section below.

In vitro studies. We used GAINS to determine the fluorescence intensity profile with increasing concentrations of NIR contrast agents indocyanine green (ICG) and LS30135 (Fig. 2a). In the 1 nM to 10 nM
range, significant fluorescence was detected, but the signal is close to the sensor noise floor, indicating
noise contribution to the net intensity signal. The intensity did not follow a linear trend. A similar profile was observed when signal-to-background ratios (SBRs) were plotted against concentration (Fig. 2b).
Therefore, there was no appreciable increase in fluorescence intensity (Fig. 2a) or the SBR (Fig. 2b)
Scientific Reports | 5:12117 | DOI: 10.1038/srep12117
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Figure 2. Graphs from phantom experiments for system characterization showing SBR and depth
resolution information. (a) Fluorescence intensity response with varying concentrations of ICG and LS301.
(b) The SBR for different concentrations of ICG and LS301. (c) SBR for different depths for 1 μ M ICG. (d)
SBR for different depths with 3 mm straws, containing 1μ M ICG, positioned 7 mm apart.

from 1 nM to 10 nM. At concentrations higher than 10 nM, we observed a rapid increase in the fluorescence intensity and SBR with increasing molecular probe concentrations. The result suggests that
the GAINS was able to detect 1 nM solutions of both ICG and LS301, while maintaining an SBR of
≥ 1.2 (Fig. 2b). This threshold represents the system’s detection limit in homogenous dimethyl sulfoxide
(DMSO) solution.
Analysis of depth and spatial resolution shows that the system is capable of detecting 1 μ M ICG inside
a tissue mimicking phantom up to a depth of 5 mm and can resolve two 3 mm diameter objects kept
7 mm apart up to a depth of 5 mm with an SBR of ≥ 1.2 (Fig. 2c,d). At the surface, the SBR for 1 μ M ICG
was 4.9 (Fig. 2c). This is much lower than the SBR observed for 1 μ M solution of ICG in DMSO, which
was used to calculate the GAINS’ detection limit (Fig. 2b). Whereas DMSO solvent has minimal scattering and absorption of light at NIR wavelengths, the tissue mimicking liquid phantom (intralipid and
India ink37) used for depth sensitivity measurement has significantly higher scattering and absorption
than DMSO. As a result, the background signals were higher for depth than sensitivity detection experiments, leading to a decrease in the SBR for studies with tissue phantoms at equivalent ICG concentration.
Time needed for complete surgical resection of tumors can vary from minutes to several hours.
Surgeons are trained to have very steady head movements during tumor removal, but they may experience involuntary head movement. Such motions could cause inaccurate fluorescence overlay if the image
becomes out of focus. Our tests indicate that if an object is within ± 2.54 cm of the focal plane of the
camera at the typical working distance of 50 cm, the accuracy of the fluorescence overlay on the color
image will be within 670 μ m. Because involuntary head movement and breathing are within the tested
range, the error in fluorescence overlay will be minimal. As a result, there is no need to keep GAINS
perfectly stationary during surgery.

In vivo mouse studies.

We used a subcutaneous breast cancer mouse model to test in vivo GAINS
function. Using LS301 fluorescence, the GAINS clearly identified all tumors (n =  10 mice), with a mean
SBR of 1.21 ±  0.1 and guided resection in real-time (Fig. 3). The fluorescence signal in the tumors was
significantly higher than surrounding tissue (P <  0.05). Histologic analysis confirmed resected tissue as
cancerous. In the metastatic mouse model of ovarian cancer, the GAINS identified 27 tumor nodules
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Figure 3. Image-guided tumor visualization in a subcutaneous mouse model. (a) Color image of a mouse
with skin deflected showing tumor nodes. (b) NIR image showing high fluorescence areas. (c) Superimposed
color-NIR image showing high fluorescence areas accurately correspond to the tumor nodes.

in 3 mice, with a mean SBR of 1.19 ±  0.03 (Fig. 4), compared to only 10 tumor nodules identified visually alone. Several tumors that were under the visceral organs (3–5 mm deep) were not visible without
GAINS guidance. However, real-time visualization of sub-surface fluorescence-guided exploratory surgery revealed tumors that would have been otherwise left behind. The fluorescence signal from suspected
tumors were significantly higher than surrounding tissue (P <  0.05), facilitating detection of the smallest
tumors (3 mm in diameter). All resected tissues were confirmed to be tumors through infrared fluorescent protein (iRFP)38 imaging and histologic analysis, which showed close overlap of iRFP signal with
LS301 fluorescence (Fig. 5). Imaging threshold provides guidance in delineating the tumor region for
resection (Supplementary Fig. S4) and affects the accuracy of tumor detection. We used receiver operator
characteristic (ROC) analysis to determine the best imaging threshold for the metastatic mouse model.
The sensitivity and specificity of tumor detection for all images were calculated at several thresholds
within the range of 7.8% to 6.3% of maximum pixel intensity. Using the best case threshold for each
image, the sensitivity and specificity of tumor detection was calculated to be 100% and 98.33% ±  5%,
respectively. Using the average detection sensitivity and specificity for each threshold tested, ROC analysis shows that a threshold of 7.5% of maximum pixel intensity is a reasonable imaging threshold to
obtain optimal sensitivity and specificity with GAINS, due to high LS301 uptake in tumor and low
tissue autofluorescence (Fig. 5). This threshold was used to identify the tumor region prior to resection.
The threshold was manually adjusted during tumor resection to accommodate changes in the residual
fluorescence intensities. Our graphical user interface (GUI) has the option of adjusting the threshold
of the superimposed images so that only fluorescence intensity above the threshold will be displayed
in pseudocolor representation in the color-NIR channel. This approach optimizes the tumor detection
sensitivity and specificity for each case.

Human pilot studies. Clinical feasibility was demonstrated in 15 patients during SLNM after
lumpectomy/mastectomy or wide excision surgeries. Surgeons used the system comfortably, with minimal disruption to the surgical workflow. The GAINS allowed clear visualization of 30 SLNs from 10
breast cancer (Supplementary Vid. S1) and 5 melanoma (Supplementary Vid. S2) patients. Using histologic analysis as the gold standard, the GAINS had a detection sensitivity of 100% in comparison to
92.86% ±  17.5% for the blue dye and 96.43% ±  12.9% for radioactive tracking. There was no statistically
significant difference in SLN detection sensitivity by GAINS compared to radioactive tracking (P =  0.34)
or blue dye tracking (P =  0.36) methods. In one melanoma patient (Fig. 6), the blue dye did not identify
Scientific Reports | 5:12117 | DOI: 10.1038/srep12117
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Figure 4. Image-guided exploratory tumor resection in a metastatic mouse model. (a) Color
image showing a large abdominal tumor (marked 1). (b) NIR image showing a high fluorescence area
corresponding to the visible tumor (marked 1) and two other areas (marked 2 and 3). (c) Superimposed
image showing color-NIR overlay image.

two deep-seated SLNs. Similarly, in one breast cancer patient, initial visual inspection did not reveal the
SLN (Fig. 7) and in another patient, radioactive tracking was unable to identify two SLNs. In all these
cases, the LNs were clearly identified by GAINS. Although the imaging depth with reasonable resolution
is about 5 mm, high fluorescence signal from deep-seated SLNs is readily projected to the surface, allowing visualization of SLNs at >5 mm deep after deflection of the overlying tissue layer (Fig. 8). This finding
demonstrates the potential clinical utility of the system for rapid identification of SLNs during surgery.

Discussion

We have developed a wearable FIGS system that can provide accurate intraoperative visualization of tumors and SLNs in real-time. The ability to detect low NIR fluorescence signal favors the use of GAINS for
molecular imaging of low- and high-expression cancer biomarkers. We used lightweight components that
are robust, durable and ergonomic. Our compact design allowed dramatic reduction of hardware footprint in the space-starved OR, compared to large standalone systems such as early version FLARE24 and
SPY26 systems. Compact camera design and ergonomic HMD allow wearability and hands-free functionality with minimal training requirements, compared to handheld guidance systems such as Fluobeam25
and PDE27 that disrupt the normal surgical workflow. The position adjustable camera mounted on the
HMD ensures matching of camera and surgeon’s FOV. Our robust image processing algorithm generates composite color-fluorescence images in real-time that are simultaneously displayed on an HMD
and an adjacent personal computer (PC) allowing non-disruptive information display to the operating
surgeon and simultaneous information availability to the surgical team in the OR. These features are
not available in other FIGS systems24–27. The software and GUI are easy to use and compatible with any
Windows-based PC. Importantly, superimposed fluorescence information on the normal visual landscape, allows rapid intraoperative visualization of tumors.
In conjunction with LS301, our method clearly identified local and metastatic tumors in murine cancer models, demonstrating the potential for using GAINS to improve the accuracy of tumor resection
and decrease the rates of repeat surgeries. Our method allows SLNM with relatively low concentrations
of the NIR contrast agent, eliminating exposure to ionizing radiation and minimizing the risk of adverse
reactions in patients9. The GAINS SLN detection sensitivity was slightly higher than radioactivity and
blue dye tracking, although we did not find any statistically significant differences between the methods.
Scientific Reports | 5:12117 | DOI: 10.1038/srep12117
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Figure 5. Accuracy of tumor detection in metastatic model. (a) iRFP image of harvested organs and
tumors from one of the mice showing confirmatory high signal from tumors. (b) Fluorescence microscopy
revealed good co-localization (yellow) of iRFP signal (green) and LS301 fluorescence (red). (c) Histological
confirmation of the same slide showing cancerous growth corresponding to the areas marked by iRFP
and LS301 fluorescence. (d) ROC curve for GAINS tumor detection sensitivity and specificity at different
imaging thresholds.

Figure 6. Melanoma patient SLNM showing excised SLN not identified by blue dye. (a) Color image
showing no blue dye signal although radioactively hot region was detected. (b) NIR image showing high
fluorescence area. (c) Superimposed image showing high fluorescence corresponding to the hot area.
Scientific Reports | 5:12117 | DOI: 10.1038/srep12117
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Figure 7. Breast cancer patient SLNM showing non-apparent SLN by visual inspection. (a) Color
image showing the absence of blue dye. (b) NIR image showing high fluorescence area and (c) NIR-color
superimposed image.

Figure 8. The SLN was apparent after superficial tissue layer was retracted. (a) Color image showing
retracted tissue layer and visible blue spot from blue dye. (b) NIR image showing a larger clear high
fluorescence area. (c) Color-NIR image showing fluorescence corresponding to the blue dye spot.

Our findings agree with previous studies that have showed ICG fluorescence has comparable or better
SLN detection sensitivity compared to radioactivity and blue dye methods10,39–42. Although other emerging clinical systems have reported capability of fluorescence detection in the OR, this is the first demonstration of “direct” visualization of NIR fluorescence-color images by surgeons.
A current limitation is the lack of automated focusing, which may lead to image blurring due to large
changes in viewing distance. We also currently require a wired connection to a PC for final image processing that restricts the user’s radius of movement. We envision future versions that will automate detection of working distance and adjust the focus according to the working distance of users. We currently
use a single camera to capture the user’s FOV, which is displayed in 2D. Future versions will transition
to a two-camera stereoscopic system to allow 3D information capture and display for enhanced surgical
guidance. We are also developing a robust wireless transmission of image data to enable constraint-free
movement. This feature will enable telemedicine applications, remote guidance from experts, and remote
training of surgical fellows. Low-cost prototype development and a minimal learning curve for the user
favors the use of GAINS in low-resource areas.
In summary, we have developed an ergonomic wearable real-time fluorescence image guidance
system that has high detection sensitivity and resolution. The GAINS was able to address successfully
the existing limitations of current image guidance systems, including large hardware footprint, field of
view mismatch, disruptive information display and real-time image guidance. In conjunction with a
tumor-selective NIR probe, the GAINS successfully detected tumors and occult metastatic nodes with
high accuracy for guided tumor resection in rodents. Importantly, the GAINS was successfully implemented in the OR for identifying SLNs in human breast cancer and melanoma patients with equivalent
Scientific Reports | 5:12117 | DOI: 10.1038/srep12117
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or better accuracy than standard methods, although larger sample size is needed to validate this finding.
Features such as the non-disruptive real-time image guidance and the need for minimal training will
potentially facilitate wide adoption of this technology by clinicians. Further improvements will enable
the detection of microscopic lesions in the surgical field, which might otherwise be missed, and possibly
prevent damage to nearby uninvolved vital structures such as nerves.

Materials and Methods

All the animal experiments were conducted in compliance with the requirements for the care and use
of laboratory animals in research, and the protocol was approved by the Washington University Animal
Studies Committee. The human procedures were carried out in accordance with the approved guidelines
by the Institutional Review Board of Washington University. Informed consent was obtained from all
patients for this United States Health Insurance Portability and Accountability Act compliant study.

Contrast Agents. ICG (Cardio green, Sigma-Aldrich, St. Louis, MO) and LS30135 were used as
NIR contrast agents. Clinical grade ICG for human SLNM was provided by the Siteman Cancer Center
(Washington University in St. Louis, MO). ICG and LS301 have similar spectral profiles, allowing the
translation of findings with the tumor-targeted LS301 in small animals to humans using FDA- approved
ICG, under similar conditions, without major changes in the detection scheme.
GAINS development. GAINS conceptual design is summarized in Fig. 1a. To maximize spectral sep-

aration and minimize light leakage, we recorded an excitation scan of ICG using a fluorimeter (Horiba
Jobin) to identify the best excitation wavelengths (Supplementary Fig. S1). We then measured the spectral profiles of LEDs using a spectrometer (Ocean Optics) to identify suitable LEDs and the appropriate
excitation and emission filters.
The NIR source (Fig. 1b) consists of 760 nm LEDs (Roithner, Vienna, Austria) with 769 ±  41 nm
bandpass filters (Semrock, Rochester, NY). The LED numbers and positions (Supplementary Fig. S2)
were optimized using simulations (LightTools). A prototype with a light output of 5 mW/cm2 at a distance of 50 cm was used. White flashlights or surgical light (Steris, Mentor, OH) covered with shortpass
filters (Cool mirror 330, 3M, St Paul, MN) served as the white light source (Supplementary Fig. S2).
The imaging module collects combined color-NIR signal via a custom F/1.75 glass lens (Supplementary
Fig. S3). The incoming signal was divided into visible and NIR components by a custom dichroic beamsplitter cube and directed to a color and NIR complementary metal-oxide semiconductor (CMOS) sensor (Aptina, San Jose, CA). The NIR and color sensors were co-registered (disparity < 0.1 mm at 50 cm
distance). An 805 nm longpass and a 694 nm shortpass filter (Semrock, Rochester, NY) were placed
in front of the NIR and color sensors, respectively, which work in stereoscopic mode (25 MHz clock
frequency, 24p frames per second (fps)). A single pair low-voltage differential signaling communicated
16-bits data (8-bits from each sensor) to the processing module at 480 MHz (25 MHz × 18) data transmission rate (Supplementary Table S1).
The processing module consists of a customized printed circuit board connection board and a
field-programmable gate array integration module (Opal Kelly, Portland, OR). The printed circuit
board powers the imaging module and deserializes the imaging data, which were pre-processed on the
field-programmable gate array via optimized Verilog code, and buffered in the on-board 64MB DDR
SDRAM. The pre-processed data were transmitted through a high-speed USB 2.0 port to a PC (or laptop). The PC runs C+ + program using OpenCV and QT C+ + libraries that can execute on any regular Windows x64 PC, without extra software and configuration. The program generates superimposed
color-NIR images, creates a GUI that gives access to functions such as display/store/process image data
and duplicates images for display on the PC and an HMD module simultaneously. The GUI also allows
the use of different exposure times for the photon-saturated visible channel and photon-starved NIR
channel, as well as a color correction for best image quality.
The display module consists of a 1080p high-resolution HMD (Carl Zeiss, Oberkochen, Germany).
Adjustable mechanical mounting and a counter balance for the imaging module were added to match
the camera and user FOV for improved user experience (Fig. 1c).

In vitro phantom studies. All characterization studies were performed at 50 cm imaging distance,

5 mW/cm2 illumination, and 24p fps.
For detection sensitivity, spatial average intensity (30 ×  30 pixels) was extracted from GAINS images
of freshly prepared triplicate samples with different concentrations of ICG (300 pM–50 μ M) and LS301
(1 nM–10 μ M) dissolved in DMSO and imaged in clear glass vials. The spatially averaged intensity values
were plotted against concentration to create the intensity detection profile for GAINS. The SBR was calculated for each concentration by using images acquired in pure DMSO as the background and plotted
against dye concentration.
For depth sensitivity, plastic straws of 3 mm diameter were filled with 1 μ M ICG and imaged at dif′

ferent depths in a tissue mimicking phantom (μ a =  0.1, μs =  5 cm−1), prepared using intralipid and 2%
India ink37. Pixel intensities corresponding to multiple points on the straw and background were used to
calculate SBRs and plotted against depth. For depth resolution, two 3 mm straws filled with 1 μ M of ICG
Scientific Reports | 5:12117 | DOI: 10.1038/srep12117
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were kept 7 mm apart and imaged at various depths in the tissue mimicking phantom. The signal intensities from a cross section of the image were used to create intensity maps and plotted against the depth.
Error in color-NIR superimposition was measured by focusing the camera at 50 cm and imaging a target
at 50 cm ±  5 cm.

In vivo mouse studies.

Six to eight-week-old nude mice (n =  10) were injected subcutaneously
into both flanks with 5 ×  105 4T1luc murine breast cancer cells. At 5–7 mm tumor size (7–10 days
post-implantation), these mice received lateral tail vein LS301 (100 μ L, 60 μ M in 20% aqueous DMSO)
injection. At 1, 4 and 24 h post-injection, the mice were imaged noninvasively using the Pearl small
animal imager (LI-COR, Lincoln, NE) and the GAINS. After 24 h, the GAINS was used for intraoperative imaging and image-guided resection of tumors. The resected tissues were preserved for histologic
analysis.
Additional 6–8-week-old nude mice (n =  3) were injected intraperitoneally with 1 ×  107 SKOV3
human ovarian cancer cells, stably transfected with iRFP38. (These cells were kindly provided to us by
Dr. Buck E. Rogers, Department of Radiation Oncology at Washington University in St. Louis, MO).
When tumors were palpable (5–10 mm, 3 weeks post-implantation), mice received lateral tail vein LS301
(100 μ L, 60 μ M in 20% aqueous DMSO) injection and were imaged noninvasively using the Pearl system
and GAINS at 1, 4, and 24 h post injection. At 24 h post injection, GAINS guided the intraoperative
tumor visualization and resection. Resected tissue were imaged for iRFP signal using the Pearl system
and then frozen for histologic analysis for determination of GAINS tumor detection sensitivity and specificity. The imaging threshold was varied retrospectively from 6.3% to 7.8% of maximum pixel intensity,
and the sensitivity and specificity were calculated for each threshold. ROC analysis was used to calculate
the optimal imaging threshold for this model.

Histology.

Fresh-frozen, 10 μ m tissue sections were imaged for NIR fluorescence, stained with hematoxylin and eosin (H&E) and the same areas were imaged under brightfield for co-registration with NIR
fluorescence using an epifluorescence microscope (BX51 Olympus, Center Valley, PA).

Pilot human studies. Participants were breast cancer patients (n =  10) undergoing a lumpectomy,

partial mastectomy, or radical mastectomy, as well as melanoma patients (n =  5) undergoing wide
excision of skin lesions, along with SLNM. Breast cancer patients, were given post-anesthesia, peritumoral injection of a mixture of 99 mTc-sulfur colloid (834 μ Ci) and methylene blue (5 mL of 1% solution)
immediately followed by ICG (5 mg/mL; 5 mL) and site massage for approximately 5 min. At 10–15 min
post-injection, the surgeon removed the tumor mass. A handheld gamma probe guided site of axillary
incision and invasive SLN identification, which were then examined for the presence of blue color and
visualized using the GAINS via ICG fluorescence. The cavity was inspected with the GAINS to identify
other fluorescent SLNs, which were then checked for blue color and radioactivity, before excision and
preservation for histology. A similar procedure was followed in melanoma patients, except that only
1 mL of ICG solution (5 mg/mL) was injected. In all cases, the GAINS was operated at 24p fps with a
40-millisecond acquisition time. NIR-white light illumination during system usage was provided by our
illumination module.

Statistical Analysis. Statistical analysis was performed using OriginPro8 (OriginLab Corp.,
Northampton, MA). SBRs, sensitivity, and specificity were expressed as mean and standard deviation.
Paired t-tests were used to compare fluorescence signal in tumors and background tissue in mouse
models and sensitivity of SLN detection by GAINS, radioactivity, and blue dye methods. P <  0.05 were
considered statistically significant.
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